A. Misra, A.K. Shasany, A.K. Shukla, M.P. Darokar, S.C. Singh, V. Sundaresan, J. Singh, G.D. Bagchi, S.P. Jain, D. Saikia and S.P.S. Khanuja
Published August 10, 2010
Genet. Mol. Res. 9 (3): 1535-1544 (2010)
DOI 10.4238/vol9-3gmr785

About the Authors
A. Misra, A.K. Shasany, A.K. Shukla, M.P. Darokar, S.C. Singh, V. Sundaresan, J. Singh, G.D. Bagchi, S.P. Jain, D. Saikia and S.P.S. Khanuja

Corresponding author: 
A.K. Shasany
E-mail: akshasany@yahoo.com

ABSTRACT

The genus Swertia is well known for its medicinal properties, as described in the Indian pharmacopoeia. Different members of this genus, although somewhat similar in morphology, differ widely in their pharmacological and therapeutic properties. The most important species of this genus, with maximal therapeutic properties, is S. chirayita, which is often adulterated with other less-potent Swertia spp. There is an existing demand in the herbal drug industry for an authentication system for Swertia spp, in order to enable their commercial use as genuine phytoceuticals. To this end, we used amplified fragment length polymorphism (AFLP) to produce DNA fingerprints for six Swertia species. Nineteen accessions (2 of S. chirayita, 3 of S. angustifolia, 2 of S. bimaculata, 5 of S. ciliata, 5 of S. cordata, and 2 of S. alata) were used in the study, which employed 64 AFLP selective primer pairs. Only 46 selective primer pairs were found to be useful for all the accessions. A total of 5312 fragments were produced by these 46 primer pairs. Species-specific markers were identified for all six Swertia species (131 for S. chirayita, 19 for S. angustifolia, 181 for S. bimaculata, 47 for S. ciliata, 94 for S. cordata, and 272 for S. alata). These AFLP fingerprints of theSwertia species could be used to authenticate drugs made with Swertia spp and to resolve adulteration-related problems faced by the commercial users of these herbs.

Key words: Adulteration; DNA fingerprinting; Crude drug